Venous sinus stenosis is the most common cause of pulsatile tinnitus, which can be severely disabling. Image: Sebra/stock.adobe.com. Sonorous Neurovascular has received US Food and Drug Administration (FDA) approval to begin a pivotal trial of a purpose-built stent for treating pulsatile tinnitus caused by venous sinus stenosis....
Continue reading at Hearing Practitioner Australia
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiologists at this stage — the trial has only received FDA approval to begin; no efficacy or safety data are yet available. Audiologists managing pulsatile tinnitus patients may wish to monitor this trial's progress.
If the BosSTENT pivotal trial succeeds, it could establish the first purpose-built interventional device for venous sinus stenosis–related pulsatile tinnitus, expanding the treatment pathway beyond audiology into neurovascular care.
- 01FDA has approved Sonorous Neurovascular to begin a pivotal (large, definitive) clinical trial of the BosSTENT.
- 02The BosSTENT is specifically designed to treat pulsatile tinnitus caused by venous sinus stenosis (narrowing of a vein near the brain).
- 03This is a regulatory milestone — no trial results or safety/efficacy data have been reported yet.
- 04Pulsatile tinnitus is a subset of tinnitus with an identifiable vascular cause, distinct from the more common non-pulsatile form.
- 05The device targets a gap in current treatment options for this specific tinnitus subtype.
The BosSTENT is a purpose-built stent designed to treat pulsatile tinnitus caused by venous sinus stenosis.
press releaseunclearThe FDA has approved Sonorous Neurovascular to begin a pivotal clinical trial of the BosSTENT.
press releasesupported